Scholars Central

Conference abstractPublished 2013

Pregnancy outcomes following gabapentin use: Results of a prospective comparative cohort study

Authors: Adrienne Einarson RN

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background:Gabapentin (Neurontin®) is an antiepileptic drug designed to treat partial seizures and is a γ -aminobutyric acid (GABA) analog that differs both structurally and pharmacologically from other classes of antiepileptic drugs (AEDs). However, despite the increasing number of patients receiving gabapentin for other indications, there is only limited information regarding the safety of this medication when used during pregnancy. Objectives: 1. Determine whether first trimester use of gabapentin is associated with an increased risk for major malformations; 2. examine rates of spontaneous abortions (SA), therapeutic abortions (TA), stillbirths, mean birth-weight and gestational age at delivery; 3. Examine rates of Poor Neonatal Adaptation Syndrome (PNAS) following late pregnancy exposure. Methods: The study design was prospective, where women were included who initially contacted services in 6 countries between 5-8 weeks and compared to a comparison group of women exposed to non-teratogens., collected in a similar fashion. Results: We have data on (n=223) pregnancy outcomes exposed to gabapentin and (n=223) unexposed pregnancies. The rates of major malformations were similar in both groups (p=0.845). There was a higher rate of preterm births; (p=0.019) and low birth weight <2500 grams (p=0.033) in the gabapentin group. Among infants who were exposed to gabapentin up until delivery, 23/61 (38%) were admitted to either the Neonatal intensive care unit (NICU) or Special Care Nursery (SCN) for observation and/or treatment, versus 6/201(2.9%) live births in the comparison group (P<0.001). There were two cases of possible PNAS, in neonates exposed to gabapentin close to delivery, compared to none in the comparison group, although it must be noted that these infants were concomitantly exposed to other psychotropic drugs. Among the women who took gabapentin, the major indications were pain n=90 (43%) and epilepsy n=71 (34%); the remainder were for other indications, mostly psychiatric. Conclusion: Our results suggest that although this sample size is not large enough to make any definitive conclusions, gabapentin use in pregnancy does not appear to increase the risk for major malformations. This finding and the increased risk for low birth weight and preterm birth requires further investigation.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Neurology & Neurophysiology
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Adrienne Einarson RN”